Radiation Therapy for Endometrial Cancer

Radiation therapy is one of the most common treatments used after surgery for endometrial cancer, and in some cases it serves as the primary treatment when surgery is not possible. Most patients with endometrial cancer are diagnosed at an early stage and treated first with a hysterectomy, after which the decision about whether to add radiation depends on a combination of tumor characteristics and, increasingly, the tumor’s molecular profile. The landscape has shifted considerably in recent years, with newer techniques reducing side effects and molecular testing allowing some patients to safely skip radiation altogether.

Two Main Types of Radiation

When doctors recommend radiation for endometrial cancer, they are usually talking about one of two approaches, or sometimes both used together. The first is vaginal cuff brachytherapy, an internal treatment where a small applicator is placed into the vagina to deliver a concentrated dose of radiation to the top of the vagina (the “cuff” left after hysterectomy). This is where the cancer is most likely to come back locally. Sessions are short, and the radiation stays focused on a small area, which keeps side effects relatively mild.

The second approach is external beam radiation therapy, or EBRT, which targets a wider area including the pelvis and sometimes the lymph nodes along the aorta. EBRT is typically delivered daily over several weeks and treats the surrounding tissues more broadly. The trade-off for that wider coverage is a higher chance of bowel and bladder side effects compared with brachytherapy alone.

Which type a patient receives depends on how aggressive the cancer appears. In a large hospital-based study of stage I endometrial cancer, brachytherapy alone accounted for about 78% of radiation treatments in the lowest-risk group but dropped to around 36% in the highest-risk subgroup, with EBRT use rising correspondingly.¹ For stage II disease, a meta-analysis found that EBRT with or without brachytherapy reduced locoregional recurrence compared with brachytherapy alone.²

How Doctors Decide Who Needs Radiation

The traditional approach to deciding on radiation has relied on risk factors visible under a microscope and during surgery: how deeply the tumor invaded the uterine wall, the tumor’s grade (how abnormal the cells look), whether cancer cells were found in lymph or blood vessels, and whether lymph nodes were involved. Low-grade, shallow tumors confined to the uterus are considered low risk, and most of those patients do well with surgery alone. As the depth of invasion increases, the grade worsens, or lymph nodes test positive, the likelihood of recurrence rises and radiation becomes more strongly recommended.

What has changed dramatically is the integration of molecular testing. The Cancer Genome Atlas identified four molecular subtypes of endometrial cancer, and a practical classification system called ProMisE translates those subtypes into categories that directly affect treatment decisions.³ The subtypes that matter most for radiation decisions are POLE-mutant tumors, which have an exceptionally good prognosis, and p53-abnormal tumors, which behave aggressively regardless of how they look under a microscope.

Molecular Classification Is Changing Who Gets Treated

The PORTEC-4a trial, published in The Lancet Oncology, tested whether molecular profiling could safely guide adjuvant treatment in women with high-intermediate-risk endometrial cancer. The results were striking: individualizing treatment based on the molecular risk profile spared 46% of patients with a favorable profile from adjuvant radiation entirely, without compromising locoregional control.⁴ That is a significant number of patients who, under older guidelines, would have received radiation they did not need.

POLE-mutant tumors deserve special attention. An individual patient data meta-analysis found that patients with POLE-mutant endometrial cancers had very low recurrence rates and did not appear to benefit from adjuvant therapy.⁵ Prospective data from PORTEC-4a reinforced that de-escalating therapy by omitting adjuvant treatment is safe for most stage I and II POLE-mutant cancers.⁶ When the recurrence rates are already so low and salvage treatment is highly effective, adding radiation offers little benefit and only side effects.

On the other end of the spectrum, p53-abnormal tumors carry a substantially worse prognosis. Molecular analysis of the PORTEC-3 trial showed that patients with p53-abnormal cancers had a five-year recurrence-free survival of about 59% with chemoradiation compared with 36% with radiation alone.⁷ For these patients, more intensive treatment clearly matters.

When Chemotherapy Is Added to Radiation

For patients with high-risk endometrial cancer, the question of whether to combine chemotherapy with radiation has been a major area of research. The PORTEC-3 trial compared chemoradiation (radiation plus cisplatin followed by carboplatin and paclitaxel) against radiation alone. Five-year overall survival was about 82% with chemoradiation versus 77% with radiation alone, a difference that did not reach statistical significance. However, five-year failure-free survival was significantly better with the combination: roughly 76% versus 69%.⁸

The molecular subgroup analysis made the picture clearer. The benefit of adding chemotherapy was concentrated in p53-abnormal tumors. Patients with POLE-mutant tumors had excellent outcomes regardless of treatment arm, and those with mismatch repair-deficient or no-specific-molecular-profile tumors showed no statistically significant difference between the two approaches.⁹ This has reinforced the shift toward using molecular classification to decide not just whether to give radiation, but how aggressively to treat.

Modern Techniques That Reduce Side Effects

The way external beam radiation is delivered has improved substantially. Older three-dimensional conformal radiation therapy (3D-CRT) shapes beams to the treatment area but still irradiates a fair amount of surrounding bowel. Intensity-modulated radiation therapy (IMRT) uses computer-optimized beam patterns to concentrate the dose more tightly on the target while sparing normal tissues. In a comparative study of endometrial cancer patients, moderate-or-worse acute gastrointestinal toxicity was about 11% with IMRT versus 19% with 3D-CRT, and severe late gastrointestinal toxicity at three years was roughly 2% with IMRT versus 5% with 3D-CRT.¹⁰

A French multicenter trial specifically evaluating IMRT for endometrial cancer found that about 27% of patients developed at least one moderate gastrointestinal side effect (mostly diarrhea during weeks four and five of treatment), and no severe gastrointestinal events were recorded. By fifteen weeks after treatment, only a handful of patients still reported any bowel symptoms.¹¹

Field size also matters. A study comparing standard pelvic fields to smaller, more targeted fields found that diarrhea occurred in 75% of patients treated with extended fields versus about 36% of those treated with smaller fields. Nausea followed a similar pattern, and no cases of small bowel obstruction occurred in the smaller-field group, compared with four cases in the standard-field group.¹²

Accuracy during treatment is another area of progress. A study using gold fiducial markers implanted at the vaginal cuff showed that the median positional shift needed to correct patient setup was about 9 millimeters, and shifts of a centimeter or more were needed in 43% of treatments.¹³ Without image guidance, those shifts could mean part of the target gets underdosed while healthy tissue gets irradiated unnecessarily.

Quality of Life After Radiation

The PORTEC-2 trial, which compared pelvic EBRT with vaginal brachytherapy alone in intermediate-risk patients, provided some of the best quality-of-life data available. Patients who received brachytherapy alone reported better social functioning and significantly fewer bowel symptoms, including less diarrhea, less fecal leakage, and less need to stay near a toilet.¹⁴ These differences persisted at the five-year follow-up.¹⁵

Sexual function, however, was affected similarly by both types of radiation. Both treatment groups reported lower sexual functioning and more sexual symptoms compared with the general population at five years.¹⁶ Vaginal shortening and stenosis (narrowing) can occur after either brachytherapy or EBRT and may develop gradually over months to years. This is one reason vaginal dilator therapy is commonly recommended during survivorship.

Vaginal Dilator Therapy and Adherence

Vaginal dilator use after radiation is widely recommended to prevent or reduce vaginal stenosis, but the reality of adherence is sobering. A randomized feasibility study found that only about 20% of patients were using dilators at the recommended frequency of three times per week at six weeks after treatment, and that figure dropped to roughly 8% by six months.¹⁷ When patients do use dilators consistently, the therapy helps improve vaginal length and reduce stenosis, though measurements typically do not fully return to pre-radiation levels.¹⁸ Patients who start with better vaginal elasticity tend to benefit more from dilator therapy, while those with poor elasticity before starting see less improvement.¹⁹

Another study found that among patients who did use dilators, about 81% experienced clinical benefit, with the best results in those using the device two to three times per week as prescribed.²⁰ The gap between efficacy and real-world adherence is one of the more frustrating problems in survivorship care; the tool works, but barriers like discomfort, embarrassment, lack of clear instruction, and simply forgetting prevent most patients from using it consistently.

Radiation as Primary Treatment When Surgery Is Not Possible

Some patients with endometrial cancer cannot undergo surgery because of severe obesity, heart disease, or other medical conditions that make anesthesia too risky. For these patients, radiation can serve as the definitive treatment. A study evaluating outcomes for medically inoperable patients found that up-front radiation therapy provided excellent cancer-specific survival and overall survival, with limited toxic effects.²¹ Patients with lower-risk cancers fared better than those with higher-risk tumors, as expected.

The approach typically involves a combination of EBRT and brachytherapy. A national database analysis found that brachytherapy consolidation was associated with lower mortality compared with EBRT consolidation alone in inoperable patients.²² A separate institutional study confirmed that the combination of EBRT and brachytherapy could treat medically inoperable patients with minimal risk of severe toxicity.²³ While surgery remains the preferred initial treatment, radiation-only approaches offer a genuine alternative for patients who cannot safely go to the operating room.

Treating Recurrences With Focused Radiation

When endometrial cancer comes back in a limited number of sites after initial treatment, stereotactic body radiation therapy (SBRT) has emerged as a useful tool. SBRT delivers very high doses in a small number of sessions (typically five or fewer) with extreme precision, targeting individual metastases while largely sparing the surrounding tissue. A large Italian multicenter study treated 157 patients with oligometastatic uterine cancer, addressing 272 lesions. Complete or partial responses were seen in about 84% of lesions. For lesions that achieved a complete response, the two-year local control rate was over 92%.²⁴ Lymph node metastases, smaller tumors, and higher radiation doses were all associated with better responses.

A smaller single-institution study found two-year local control rates of about 77% for oligometastatic uterine cancer treated with SBRT, with nodal recurrences being the most common target.²⁵ SBRT is not a substitute for systemic therapy in patients with widespread metastatic disease, but for isolated recurrences, it can provide durable local control and sometimes delay or avoid additional chemotherapy.

When Lymph Nodes Are Involved

Deciding how large a radiation field to use when pelvic lymph nodes contain cancer is a practical dilemma. Treating only the pelvis risks missing cancer that has spread to para-aortic nodes higher in the abdomen, but extending the field upward increases side effects. A study of patients with cancer-positive pelvic nodes (stage IIIC1) who received pelvic radiation found that only about 6% developed isolated para-aortic nodal recurrence outside the radiation field, and most of those patients were successfully salvaged with additional treatment.²⁶ Among the patients who did recur in para-aortic nodes, most had features suggesting aggressive disease at diagnosis, including deep muscle invasion and high tumor grade.

For patients with known para-aortic node involvement, radiation fields typically extend to include both the pelvic and para-aortic chains.²⁷ The challenge is that extended-field radiation increases the volume of bowel exposed to radiation. This is one area where newer delivery techniques like IMRT and, potentially, proton therapy may be particularly valuable.

Racial and Socioeconomic Disparities in Radiation Access

Not all patients who should receive radiation actually get it, and the gaps fall along predictable lines. A study of high-risk early-stage endometrial cancer found that African American, Hispanic, and Asian patients were all less likely to receive recommended adjuvant radiation compared with non-Hispanic white patients. Lower household income, lack of insurance, treatment at non-academic hospitals, and greater distance to treatment facilities were all independently associated with omission of radiation, and skipping radiation was linked to worse overall survival.²⁸

Treatment differences extend to the type of radiation received as well. In a multi-institutional study of stage IIIC disease, Black patients were more often treated with EBRT alone, while a higher proportion of non-Black patients received the combination of EBRT and vaginal cuff brachytherapy, despite having similar disease characteristics.²⁹ Since the combination approach is generally considered more complete for advanced-stage disease, these disparities have real clinical consequences.

Proton Therapy and Next-Generation Approaches

Proton beam therapy is generating interest for pelvic radiation because protons deposit most of their energy at a specific depth and then stop, unlike conventional X-ray photons that pass through the body and irradiate tissues on the exit side. A dosimetric comparison found that intensity-modulated proton therapy reduced dose to the kidneys, spinal cord, and bowel compared with standard IMRT, with the most clinically meaningful reductions seen when treating the para-aortic region.³⁰

Early clinical data backs up the planning studies. A matched comparison of patients treated with proton therapy versus photon IMRT found that hematologic toxicity (drops in blood counts) was significantly less common with protons: 32% versus 80%. Severe blood count drops occurred in only 8% of proton patients compared with 36% of photon patients. This difference was driven by a roughly 40% reduction in low-dose radiation exposure to the pelvic bone marrow, where blood cells are produced.³¹ Fewer blood count drops could translate to fewer treatment delays and fewer infections, especially for patients also receiving chemotherapy. Proton therapy remains limited by availability and cost, but for patients who need extended-field treatment or combined chemoradiation, the bone marrow-sparing advantage is clinically meaningful.

Brachytherapy Applicator Design

For patients receiving vaginal brachytherapy, the type of applicator used can affect how evenly radiation is distributed. The simplest design is a single-channel cylinder, where the radioactive source moves along one central path. Multichannel applicators have additional channels around the periphery, allowing the treatment planner to shape the dose distribution more precisely. A dosimetric comparison found that multichannel applicators improved coverage of the target tissue while reducing dose to the rectum, with statistically significant reductions in rectal exposure.³² Multichannel applicators with six or more peripheral channels and inverse treatment planning optimization can produce asymmetric dose distributions tailored to each patient’s anatomy.³³ For most straightforward cases, a single-channel cylinder works well, but when the target is irregularly shaped or a critical organ like the rectum is unusually close, the multichannel approach offers a real advantage.